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ABSTRACT The biocompatibility and performance of reagents for in vivo contrast-enhanced magnetic 
resonance imaging are essential for their translation to the clinic. The quality of the surface coating of 
nanoparticle-based MRI contrast agents, such as ultra-small superparamagnetic iron oxide nanoparticles 
(USPIONs), is critical to ensure high colloidal stability in biological environments, improved magnetic 
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performance and dispersion in circulatory fluids and tissues. Herein, we report the design of a library of 
21 peptides and ligands and identify highly stable self-assembled monolayers on the USPIONs surface. 
A total of 86 different peptide coated USPIONs are prepared and selected using several stringent criteria, 
e.g., stability against electrolyte-induced aggregation in physiological conditions, prevention of non-spe-
cific binding to cells, absence of cellular toxicity and contrast-enhanced in vivo MRI. The bis-phosphor-
ylated peptide 2PG-S*VVVT-PEG4-ol provides highest biocompatibility and performance for USPIONs, 
with no detectable toxicity or adhesion to live cells. The 2PG-S*VVVT-PEG4-ol coated USPIONs show 
enhanced magnetic resonance properties, r1 (2.4 mM-1.s-1) and r2 (217.8 mM-1.s-1) relaxivities, and greater r2/r1 
relaxivity ratios (>90), when compared to commercially available MRI contrast agents. Furthermore, we 
demonstrate the utility of 2PG-S*VVVT-PEG4-ol coated USPIONs as a T2 contrast agent for in vivo 
MRI applications. High contrast enhancement of the liver is achieved as well as detection of liver tumors, 
with significant improvement of the contrast-to-noise ratio of tumor-to-liver contrast. It is envisaged that 
the reported peptide coated USPIONs have the potential to allow for the specific targeting of tumors, and 
hence early detection of cancer by MRI. 
KEYWORDS: peptide, coating, iron oxide nanoparticles, biocompatibility, magnetic resonance imaging. 
 
The development of safe and high-performing nanoparticle-based contrast agents for medical imaging1 
and their translation to the clinic offers high potential to greatly improve both diagnosis and treatment, 
also known as theranostic,2 of various diseases such as cancer and neurological pathologies. Superpara-
magnetic iron oxide nanoparticles (SPIONs) are the most successful nanomaterial-based contrast agents 
translated today for human utilization for T2-weighted magnetic resonance imaging (MRI), and are gen-
erally considered for both diagnosis and therapeutic uses.3–10 Importantly, ultra-small superparamagnetic 
iron oxide nanoparticles (USPIONs) have been proposed as an alternative to the well-established gado-
linium-based contrast agents (GBCA) for MRI, particularly for patients with chronic kidney diseases at 
risk of nephrogenic systemic fibrosis.11 In spite of the growing variety of SPION formulations approved 
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by the Food and Drug Administration (FDA) for use in humans as iron deficiency therapeutics or as MRI 
contrast agents, e.g., Feridex®, Umirem®, Resovist®, the constant reevaluation of the potential risk of 
side-effects and efficacy led in most cases to their subsequent withdrawal from the market.12 It is thus 
critical to further improve the biocompatibility and performance of SPIONs and create innovative solu-
tions enabling their translation for clinical utilization. 
The coating of USPIONs is a key component to ensure biocompatibility and maintenance of high per-
formance during in vivo imaging. The coating protects the USPIONs core from a challenging biological 
environment, hence preventing any undesired decomposition or aggregation. The coating may also control 
their interactions with the body’s tissues and fluids, and allow the USPIONs to target specific organs and 
areas in the body, e.g., tumors. During MRI acquisition, the proximity of protons to the water present in 
tissues and the USPIONs surface facilitates the signal. Hence the quality and thickness of the USPIONs 
coating influences the magnetic performance of the contrast agent.13 Current FDA-approved SPIONs are 
formulated as either individual or cluster of iron oxide nanoparticles encapsulated in highly hydrophilic 
synthetic or biological polymers, e.g., polyethylene glycol, polysaccharides, dextran.3,14,15 Despite the nu-
merous advantages of polymer coatings, e.g., biocompatibility, increased hydrophilicity and further bio-
functionalization,16 such formulations may increase their hydrodynamic size and potentially affect their 
magnetic resonance performance.13 
We have previously demonstrated the utilization of well-designed short peptides and ligands to form 
highly stable and thin self-assembled monolayers (SAM) for the coating of noble metal nanoparticle 
probes dedicated to bioimaging applications, e.g., gold, silver.17–21 The peptide coating greatly increases the 
colloidal stability and biocompatibility of noble metal nanoparticles and prevents any major problems 
encountered during biological applications, e.g., electrolyte-induced aggregation, ligand exchange, non-
specific binding to biomolecules or cell membranes, and cell toxicity. Furthermore, the peptide coating 
offers the possibility to functionalize the nanoparticles with stoichiometric control with targeting moieties, 
e.g., peptides, proteins, via either affinity or covalent conjugation. Recently, we demonstrated the use of 
peptide coated gold nanoparticles to probe specific cell targets22 and to enable their specific internalization 
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into confined areas, i.e., porous protein cages cores,23 which are otherwise not possible with bulky nano-
materials. 
Herein, we report the design of a library of short peptides and ligands to create biocompatible peptide 
coated USPIONs for in vivo contrast-enhanced MRI applications. A total of 86 different peptide coated 
USPIONs were prepared and we identified the highest performing candidates via a stringent selection 
process, e.g., size mono-dispersity, long-term stability in physiological conditions, cytotoxicity and cell 
non-specific biding, in vitro and in vivo magnetic resonance performances. We demonstrated the greater 
stability of bis-phosphorylated anchor groups located at the foot of peptides and ligands, compared to 
mono-phosphorylated groups or other moieties commonly used for the coating of iron oxide 
nanomaterials, e.g., L-3,4-dihydroxyphenylalanine (DOPA).24 Specifically, the bis-phosphorylated 
peptide 2PG-S*VVVT-PEG4-ol and the mixed peptide ligand 2PG-S*VVVT-ol:(PO3H2)-S-C11-EG3-OH 
(70:30, mole:mole) coated USPIONs had the highest stability and biocompatibility over a long time in 
vitro. Importantly, they also outperformed the magnetic resonance properties of commercially available 
contrast agents, i.e., Magnevist® and Resovist®, with greater relaxivities and r2/r1 ratios, which indicates 
their utility for T2-weighted MRI applications. Most interestingly, we demonstrated the high contrast 
enhancement provided by the 2PG-S*VVVT-PEG4-ol coated USPIONs during T2-weighted MRI in liver 
in vivo and their application for the detection of liver tumors. This investigation will enable further 
development of the peptide coated USPIONs, such as biofunctionalization with biomarkers, for the 
utilization of peptide coated USPIONs for the early detection of other types of tumors and diseases by 
MRI. 
RESULTS AND DISCUSSION 
Method for the preparation and selection of peptide coated USPIONs for in vivo contrast-
enhanced MRI. In this investigation, we prepared and selected highly stable and biocompatible peptide 
coated USPIONs with the best performance as T2 contrast agents for in vivo MRI applications (Figure 1). 
In a first step (Figure 1a), the phase transfer of oleic acid coated USPIONs dispersed in chloroform to 
an aqueous phase was carried out by ligand exchange of the oleic acid coating with tetramethylammonium 
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hydroxide (TMAOH). We designed a library of 20 short peptides and ligands and tested their ability to 
form a stable SAM on the USPIONs surface via direct ligand exchange of the preliminary TMAOH coat-
ing (Figure 1b). We prepared 86 single and mixed peptide coated USPIONs and evaluated them following 
a “funnel selection process” in which a series of increasingly stringent tests were used to select the most 
performing peptide coated USPIONs contrast agents for in vivo contrast-enhanced MRI applications (Fig-
ure 1c). We evaluated each peptide coating for its ability to protect the surface of USPIONs and allow 
purification by size-exclusion chromatography (SEC), stabilize USPIONs against electrolyte-induced ag-
gregation in physiological conditions, prevent non-specific binding to live cells, present no cell toxicity 
and provide strong magnetic resonance properties in vitro and enhanced contrast during in vivo MRI. We 
evaluated the most performing peptide coated USPIONs against commercial MRI contrast agents used in 
the clinic, Resovist®, Magnevist®. 
Figure 1. Method for the preparation and selection of high-performing peptide coated USPIONs MRI 
contrast agents. a) Phase transfer of oleic acid coated USPIONs dispersed in chloroform to aqueous phase 
by ligand exchange with tetramethylammonium hydroxide (TMAOH); b) Peptide coating of water-
dispersed TMAOH coated USPIONs by ligand exchange reaction. A library of 86 candidates of single 
and mixed peptide ligand coated USPIONs was prepared and evaluated; c) Funnel selection process for 
the determination of the most performing peptide coated USPIONs contrast agent for in vivo contrast-
enhanced MRI. 
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Tailored peptide library. We designed a library of 20 short peptides and ligands to form stable SAMs 
on the surface of USPIONs (Table 1). The tailoring of peptides that will form SAMs on the surface of  
nanoparticles follows three common features: 1) a foot, to anchor the peptides onto the nanoparticle 
surface; 2) a stem, to favor peptide-peptide interactions and increase the SAM packing density, and; 3) a 
head, to improve the colloidal stability and prevent non-specific interactions with the biological 
environment.17,18,20,21 Each feature ensures then the formation of highly stable and biocompatible peptide 
coated USPIONs. 
Table 1. Peptide and ligand library design. 
Alkyl phosphorothioic 
acid ligands 
Ligands bearing phosphorylated amino acid 
anchor groups 
Peptides bearing phosphorylated amino acid 
anchor groups 
Peptide ligands bearing 
non-phosphorylated 
anchor groups 
Single phosphate Double phosphate Single phosphate Double phosphate 
(PO3H2)-S-C11-EG3-OHa 
(PO3H2)-S-C11-EG6-OHa 
(PO3H2)-S-C16-OHa 
H-S*-NH-PEG4-ol 
2PG-NH-PEG4-ol 
2PG-G-NH-PEG4-OH 
2PG-G-NH-PEG4-ol 
H-S*-C11-PEG4-ol 
2PG-S*-C11-PEG4-
ol 
H-S*SSSS-ol 
H-S*PPPT-ol 
H-S*VVVT-ol 
2PG-S*VVVT-ol 
2PG-Y*VVVT-ol 
2PG-S*VVVT-PEG4-ol 
N(Me3)-C11-PEG4-ol 
H-DVVVT-ol 
DOPA-VVVT-ol 
DOPA-VVVT-PEG4-ol 
DOPA-C11-PEG4-ol 
a The letter S is a sulfur atom in this case. 
Abbreviations: 2PG = (PO3H2)-O-CH2-CO-, 2-phosphoglycolic acid; S* and Y* = Ser(PO3H2) and 
Tyr(PO3H2) respectively; EG3-OH = -(O-CH2-CH2)3-OH; EG6-OH = -(O-CH2-CH2)6-OH; PEG4-ol = -NH-
(CH2-CH2-O)3-CH2-CH2-OH; PEG4-OH = -NH-(CH2-CH2-O)4-CH2-CH2-CO2H; C11 = -(CH2)11-; C16 = -
(CH2)16-; DOPA = L-3,4-dihydroxyphenylalanine. 
The foot of the peptide is essential to increase the SAM stability and limit peptide loss from the 
nanoparticle surface, in particular from ligand exchange reactions with small biomolecules present in the 
biological environment. Phosphate and phosphonic acid groups have a strong affinity to metals and metal 
oxides such as iron oxide surfaces.25,26 In particular, the robustness of the chemical bond formed between 
the surface of iron oxide nanoparticles and phosphorylated groups helped develop affinity 
chromatography techniques for the purification of phosphorylated peptides and protein digests of 
biological interest.27 Inexpensive protein lysates containing phosphorylated peptides such as Tryptone 
were also proposed to encapsulate iron oxide nanoparticles.28 However, although the preparation of peptide 
coated iron oxide nanoparticles from protein lysates is an attractive solution, their polydispersity and 
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quasi-random amino acid sequences limits the stability of the nanoparticles coating. Here, we designed 
peptides and ligands with a single or bis-phosphorylated foot using phosphorylated moieties such as 
phosphorothioic, phosphorylated amino acids (Ser(PO3H2) and  Tyr(PO3H2)) and 2-phosphoglycolic acid 
(2PG). We also compared the stability of phosphorylated peptide SAMs with peptides and ligands 
presenting other anchor groups used for iron oxide surfaces, i.e., quaternary amine, carboxylic acid and 
L-3,4-dihydroxyphenylalanine (DOPA).24 
Peptides and ligands with a short stem such as pentapeptides and short alkane chains form highly stable 
and dense SAMs on noble metal nanoparticles.17,18,20–23 Non-charged and non-polar stems also favor van der 
Waals interactions between peptides and ligands and increase the packing density of SAMs. Therefore 
we used pentapeptide sequences, e.g., -SVVVT-, -SSSSS- and –SPPPT-, and alkane chains, e.g., 
undecane and hexadecane.18 
We also used hydrophilic and non-charged moieties to form the heads of the peptides and ligands, e.g., 
alcohol and ethylene glycol. The hydrophilic property of the peptide head improves the water-dispersion 
of nanoparticles and ethylene glycol groups increase steric repulsion and colloidal stability, limiting non-
specific binding to biomaterials, e.g., proteins and cell membranes. Alternatively, charged moieties such 
as carboxylic acids may also improve colloidal stability, e.g., H-CALNN-OH peptide coated gold 
nanoparticles.21 However, the increased non-specific interactions with biomolecules presenting opposite 
charges is a major inconvenience to charged nanoparticle surfaces. Hence, we only included a single 
instance of carboxylic acid terminated ligand (2PG-G-NH-PEG4-OH) in our library for comparison. 
Preparation and characterization of water soluble TMAOH coated USPIONs. We mixed oleic acid 
coated USPIONs dispersed in chloroform with an aqueous solution of tetramethylammonium hydroxide 
(TMAOH) to replace the hydrophobic coating with a hydrophilic TMAOH one and so phase transfer 
TMAOH coated USPIONs into water. Electron microscopy analysis showed the conservation of the size 
of the USPIONs’ core, with an average size of 11.3 ± 1.3 nm in diameter of the oleic acid coated USPIONs 
(Figure 2A) and an average size of 10.1 ± 0.9 nm in diameter of the TMAOH coated USPIONs (Figure 
2B). The crystal structure of the USPIONs core corresponding to gamma-Fe2O3 iron oxide (maghemite) 
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was also conserved after phase transfer as shown by X-ray powder diffraction analysis (Figures 2C,D) 
and high-resolution electron microscopy (Figure 2E). The dynamic light scattering analysis of TMAOH 
coated USPIONs showed a hydrodynamic size of 10 ± 3 nm (Figure 2F and Table 2) and a zeta potential 
of -50 ± 1 mV (Table 2). 
Figure 2. Characterization of oleic acid coated USPIONs and water soluble TMAOH coated USPIONs. 
Size distribution by electron microscopy analysis of (A) 100 oleic acid coated USPIONs with average 
diameter of 11.3 ± 1.3 nm and (B) 100 TMAOH coated USPIONs with average diameter of 10.1 ± 0.9 
nm. Insets show typical images used for calculations. Scale bar is 20 nm. X-ray powder diffraction of (C) 
oleic acid coated USPIONs and (D) TMAOH coated USPIONs with 2-Theta peaks corresponding to 
gamma-Fe2O3 iron oxide, maghemite (cubic) crystal structure. (E) High-resolution electron microscopy 
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picture of oleic acid coated USPIONs with single crystallinity and lattice fringes across the entire nano-
particles corresponding to F2O3 (220). Scale bar is 5 nm. (F) Dynamic light scattering characterization of 
10 ± 3 nm TMAOH coated USPIONs (Pdi = 0.262). 
Preparation and purification of peptide coated USPIONs. We evaluated first the ability of each 
peptide and ligand from our library to stabilize USPIONs. The ligand exchange reaction of the TMAOH 
coating onto USPIONs surface with peptides and ligands was adapted from our previous work on the 
preparation of peptide coated gold nanoparticles from citrate coated gold nanoparticles,18 and the 
preparation of peptide coated magnetic iron oxide nanoparticles (IONPs) from TMAOH coated IONPs 
reported by Barch et al.. 29  Firstly, 0.1 volume of TMAOH coated USPIONs dispersed in 0.1% (w/v) 
TMAOH aqueous solution were diluted with 8.9 volumes of water and mixed with 1 volume of a 2 M 
peptide or ligand solution for an hour. This step allowed for an initial ligand exchange reaction of the 
weak TMAOH coating with peptides and ligands bearing anchor groups that strongly bond to iron oxide 
surfaces, e.g., via phosphate and phosphonic acid. Secondly, the samples were mixed with 1 volume of 
200 mM HEPES, 1 M NaCl (pH 7.4) at room temperature overnight. 
We noted here that the stability of the peptide coated USPIONs in a relatively high concentration of 
NaCl (100 mM) present in the HEPES buffer indicated that a rapid initial ligand exchange of the TMAOH 
coating occurred in the first step, since TMAOH coated USPIONs were not stable in presence of NaCl. 
The peptide coated USPIONs were then purified by size-exclusion chromatography (SEC) on Sephadex 
G25 resin to remove the excess of peptides and ligands. Sephadex G25 is a cross-linked dextran, so SEC 
also evaluated the potential for non-specific binding to biomaterials, e.g., polysaccharides. We determined 
the yield of the preparation of each peptide coated USPIONs after SEC purification by UV-visible 
spectrometry and their hydrodynamic size and zeta potential by DLS (Table 2, Figure S1). 
Table 2. Size-exclusion chromatography of single peptide coated USPIONs and characterization of zeta 
potentials and hydrodynamic sizes by dynamic light scattering. 
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Peptide ligand design Yield after SEC 
purification (%) 
DLS size 
(nm) 
Zeta potential 
(mV) 
TMAOH 0 10 ± 3 -50 ± 1 
(PO3H2)-S-C11-EG3-OH 0 - - 
(PO3H2)-S-C11-EG6-OH 0 - - 
(PO3H2)-S-C16-OH 86 ± 7 59 ± 34 -37 ± 1 
H-S*-NH-PEG4-ol 0 - - 
2PG-NH-PEG4-ol 0 - - 
2PG-G-NH-PEG4-OH 0 - - 
2PG-G-NH-PEG4-ol 0 - - 
H-S*-C11-PEG4-ol 0 - - 
2PG-S*-C11-PEG4-ol 88 ± 4 51 ± 19 -17 ± 1 
H-S*SSSS-ol 0 - - 
H-S*PPPT-ol 0 - - 
H-S*VVVT-ol 0 - - 
2PG-S*VVVT-ol 85 ± 10 18 ± 7 -16 ± 2 
2PG-Y*VVVT-ol 69 ± 6 33 ± 16 -28 ± 1 
2PG-S*VVVT-PEG4-ol 94 ± 4 18 ± 8 -14 ± 2 
N(Me3)-C11-PEG4-ol 0 - - 
H-DVVVT-ol 0 - - 
DOPA-VVVT-ol 0 - - 
DOPA-VVVT-PEG4-ol 34 ± 3 51 ± 23 -11 ± 1 
DOPA-C11-PEG4-ol 0 - - 
Data were acquired on duplicate from two experiments and presented as average and standard deviation. 
The mono-phosphorylated ligand (PO3H2)-S-C16-OH, the bis-phosphorylated ligand 2PG-S*-C11-
PEG4-ol and the bis-phosphorylated peptides 2PG-S*VVVT-ol and 2PG-S*VVVT-PEG4-ol stabilized 
the USPIONs with high yields (>80%). DLS analysis showed that only the two bis-phosphorylated 
peptides 2PG-S*VVVT-ol and 2PG-S*VVVT-PEG4-ol formed coatings with minimal hydrodynamic 
size increase (18 nm) (Table 2). We suggest that a significant increase of the peptide coated USPIONs 
hydrodynamic size indicated the formation of less organized and stable surface coatings rather than a 
compact SAM. The hypothesis was supported with the zeta potential of 2PG-S*VVVT-ol and 2PG-
S*VVVT-PEG4-ol coated USPIONs being the closest to neutral, i.e., -16 and -14 mV respectively. 
Considering the neutral heads of the peptides and ligands exposed at the surface of the USPIONs coatings 
 
 
11 
and the negative zeta potential of the initial TMAOH coated USPIONs (-50 mV), this result confirmed a 
greater coverage of the USPIONs surface than for peptide or ligand coated USPIONs with more negative 
zeta potentials (Table 2). 
Despite the similarity of the design of some peptides and ligands, we observed that specific features 
were necessary to form stable peptide coating on USPIONs (Table 2). For instance, the comparison of 
peptides with different foot design, i.e., 2PG-S*VVVT-ol, H-S*VVVT-ol, H-DVVVT-ol, DOPA-VVVT-
ol, indicated that a bis-phosphorylated anchor group provided greater stability to the peptide coating than 
other groups that are also known to have good affinity to iron oxide surface, e.g., mono-phosphorylated 
groups, carboxylic acid, DOPA. The same trends were observed with ligands designed with undecane 
stems and ethylene glycol heads, i.e., 2PG-S*-C11-PEG4-ol, H-S*-C11-PEG4-ol, (PO3H2)-S-C11-EG3-
OH, N(Me3)-C11-PEG4-ol and DOPA-C11-PEG4-ol. In the latter case, only bis-phosphorylated anchor 
groups provided sufficient stability to USPIONs. We also observed that ligands without a stem, i.e., H-
S*-NH-PEG4-ol, 2PG-NH-PEG4-ol, 2PG-G-NH-PEG4-OH and 2PG-G-NH-PEG4-ol, did not provide 
sufficient stability to USPIONs and indicated that a stem is required. 
Following the first screening of single peptide coated USPIONs, we prepared mixed ligand coated 
USPIONs with binary combinations of a peptide and a ligand from our library. As demonstrated in our 
previous studies,18,20 the combination of short peptidols and alkane ethylene glycol ligands provides highly 
stable mixed peptide coatings on metal nanoparticles. Ethylene glycol groups at the head position of 
ligands present sufficient flexibility and steric repulsion on the surface of the nanoparticles to increase 
their colloidal stability. Moreover, the neutral alcohol groups at the carboxyl-terminal position of the 
peptidols and the alkane ethylene glycol ligands help prevent from non-specific binding to charged 
molecules. We found that a SAM called Mix-matrix formed with a mixture of the pentapeptidol H-
CVVVT-ol and a short thiolated undecane ethylene glycol ligands HS-C11-EG4 provided great stability 
to gold18 and silver nanoparticles.17 Similarly, here we selected from our library 8 peptides, i.e., H-S*SSSS-
ol, H-S*PPPT-ol, H-S*VVVT-ol, 2PG-S*VVVT-ol, 2PG-Y*VVVT-ol, 2PG-S*VVVT-PEG4-ol, 
DOPA-VVVT-ol and DOPA-VVVT-PEG4-ol, and 5 ligands, i.e., (PO3H2)-S-C11-EG3-OH, (PO3H2)-S-
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C11-EG6-OH, (PO3H2)-S-C16-OH, 2PG-S*-C11-PEG4-ol and DOPA-C11-PEG4-ol. We prepared mixed 
peptide coated USPIONs with peptide to ligand molar ratios of 70:30, 50:50 and 30:70 (all mole:mole). 
The yields of the preparation of the mixed peptide coated USPIONs were determined by UV-visible 
spectrometry after SEC purification, and the hydrodynamic sizes and zeta potentials characterized by DLS 
(Table S1). A summary of the successful purifications by SEC of the mixed peptide coated USPIONs is 
presented in Table 3. 
Table 3. Qualitative summary of size-exclusion chromatography of mixed peptide coated USPIONs. 
 
(PO3H2)-S-C11- 
EG3-OH 
(PO3H2)-S-C11- 
EG6-OH 
(PO3H2)-S-C16-OH 2PG-S*-C11-PEG4-ol DOPA-C11-PEG4-ol 
Peptide to ligand 
(mole:mole) 
70:30 50:50 30:70 70:30 50:50 30:70 70:30 50:50 30:70 70:30 50:50 30:70 70:30 50:50 30:70 
H-S*SSSS-ol - - - - - - + + + 
 
  
 
  
H-S*PPPT-ol - - - - - - + + +       
H-S*VVVT-ol - - - - - - + + + 
 
  
 
  
2PG-S*VVVT-ol + + + + + + + + + + + + 
 
  
2PG-Y*VVVT-ol + - - + - - + + + + + + 
 
  
2PG-S*VVVT-PEG4-
ol 
+ + + + + + + + + 
 
  
 
  
DOPA-VVVT-ol 
 
  
 
  
 
  
 
  - - - 
DOPA-VVVT-PEG4-
ol 
 
  
 
  
 
  
 
  - - - 
A sign (+) indicates the successful purification of the peptide coated USPIONs by SEC, allowing to 
collect sufficient USPIONs for DLS and zeta potential characterization. A sign (-) indicates that no pep-
tide coated USPIONs were collected after SEC. The full dataset is presented in Table S1. 
We observed first that the ligand (PO3H2)-S-C16-OH was successful when mixed with a mono-
phosphorylated peptide. The mixed peptide coated USPIONs prepared with the bis-phosphorylated 
peptides, i.e., 2PG-S*VVVT-ol, 2PG-Y*VVVT-ol, 2PG-S*VVVT-PEG4-ol, had generally higher 
preparation yields, regardless of the second ligand type or the molar ratio. DOPA functionalized peptides 
and ligands were not able to stabilize the USPIONs even though the design of the stems and heads of the 
peptides and ligands were identical to other combinations stabilizing the USPIONs, e.g., 2PG-S*VVVT-
ol and (PO3H2)-S-C16-OH. Therefore, phosphorylated anchor groups at the foot of peptides and ligands 
improved the stability of USPIONs. For most mixed peptide coated USPIONs, hydrodynamic sizes zeta 
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potentials were consistent with the results from single peptide coated USPIONs, as we observed with low 
increases in the hydrodynamic radius, e.g., 18 nm, and large increase of the zeta potential after ligand 
exchange, e.g., -20 mV (Table S1). 
Stability of peptide coated USPIONs against electrolyte-induced aggregation. We evaluated the 
stability of the peptide coated USPIONs that largely did not bind to Sephadex G25 against electrolyte-
induced aggregation in physiological conditions and in high electrolyte concentrations to identify the most 
performing peptide coated USPIONs for in vitro and in vivo applications. Similarly to our previous studies 
on the preparation of biocompatible peptide coated gold nanoparticles,18,20 we used a normalized aggrega-
tion parameter (NAP) based on the comparison of the UV absorption of each USPIONs preparation before 
and after incubation in various conditions, i.e., NaCl concentrations from 0 to 1 M, buffers (HEPES, PBS), 
at room temperature or 37°C, and incubation times (up to 48 h). 
The evaluation of single peptide coated USPIONs revealed distinct differences in stability depending 
on the design of the peptide and ligand (Figure 3A-C). The detailed results obtained are available in 
supplementary information (Figures S2-S7). After 3 h incubation in 20 mM HEPES at pH 7.4 in NaCl 
concentrations ranging from 0 to 1 M at room temperature (Figure 3A) the bis-phosphorylated peptidols 
2PG-S*VVVT-ol and 2PG-Y*VVVT-ol coated USPIONs were the least stable and aggregated. We noted 
also that the differences in hydrodynamic sizes and zeta potentials (Table 2) between the two peptidol 
coated USPIONs were not reliable indicators of stability towards electrolyte-induced aggregation. 
Moreover, this result correlated with our previous studies with similar single peptide coated gold 
nanoparticles, e.g., H-CVVVT-ol,18 which showed that a peptidol alone is not able to stabilize efficiently 
metal nanoparticles and needs an additional ligand to form a stable SAM, e.g., Mix-matrix coated gold 
nanoparticles with the peptidol H-CVVVT-ol and the ligand HS-C11-EG4. Surprisingly, the mono-
phosphorylated ligand (PO3H2)-S-C16-OH demonstrated greater stability than the bis-phosphorylated 
ligand 2PG-S*-C11-PEG4-ol, even though the former possess only a single phosphorylation anchor group 
and lacks an ethylene glycol moiety often necessary to reduce electrolyte-induced aggregation, e.g., HS-
C11-EG4 coated gold nanoparticles.18 Most importantly, the bis-phosphorylated peptide 2PG-S*VVVT-
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PEG4-ol provided the greatest stability in all incubation conditions (Figure 3A-C) and showed no sign of 
aggregation after long incubation time even in high NaCl concentrations (1 M) and at 37°C. Interestingly 
too, the 2PG-S*VVVT-PEG4-ol coated USPIONs were purified with the greatest yield (>94%) and 
showed the lowest increase of hydrodynamic size (18 nm) and a large increase of zeta potential (-14 mV) 
(Table 2). Hence, the presence of a short hydrophilic ethylene glycol at the head of the peptide 2PG-
S*VVVT-PEG4-ol provided sufficient steric hindrance at the surface of the USPIONs to prevent 
electrolyte-induced aggregation. A similar peptide design, i.e., DOPA-VVVT-PEG4-ol, also 
demonstrated promising results in high electrolyte concentrations and after long incubation times in 20 
mM HEPES at room temperature (Figure 3B). However, it failed to remain stable at 37°C (Figure 3C). 
Figure 3. Stability of peptide coated USPIONs against electrolyte-induced aggregation. Normalized ag-
gregation parameter values of single peptide coated USPIONs: (A) after 3 h incubation at room tempera-
ture in a 20 mM HEPES buffer (pH 7.4) and a range of concentrations of NaCl; after different incubation 
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times in 20 mM HEPES and 100 mM NaCl buffer (pH 7.4) at (B) room temperature and (C) 37°C. Nor-
malized aggregation parameter values of selected mixed peptide coated USPIONs incubated for 24 h in 
20 mM HEPES and 100 mM NaCl buffer (pH 7.4) at room temperature. Mixed peptide coated USPIONs 
formed with: (D) different peptides and the ligand (PO3H2)-S-C16-OH; (E) different ligands and the pep-
tidol 2PG-S*VVVT-ol; (F) different ligands and the peptide 2PG-S*VVVT-PEG4-ol, at different molar 
ratios. Data were acquired on duplicate from two experiments and presented as average and standard 
deviation. 
The stability of mixed peptide coated USPIONs against electrolyte-induced aggregation was then eval-
uated. The detailed results are available in supplementary information (Figures S8-S45). The normalized 
aggregation parameter values of selected mixed peptide coated USPIONs incubated for 24 h in 20 mM 
HEPES buffer at pH 7.4 at room temperature are presented in Figures 3D-F. Mixed peptide coatings 
prepared with a mono or bis-phosphorylated peptide combined with the ligand (PO3H2)-S-C16-OH (Figure 
3D) were in most instances stable. Interestingly, although the mono-phosphorylated peptidols H-S*SSSS-
ol, H-S*PPPT-ol and H-S*VVVT-ol did not form stable single peptide coated USPIONs, they were rela-
tively stable when mixed with the ligand (PO3H2)-S-C16-OH. Mixed peptide coated USPIONs formed 
with the peptidols H-S*SSSS-ol, H-S*PPPT-ol or H-S*VVVT-ol and mixed with the ligand (PO3H2)-S-
C16-OH were among the most stable, however this result was not directly correlated to the preparation 
yields (Table S1) that were in most cases lower. Most mixed peptide coated USPIONs formed with the 
ligand (PO3H2)-S-C16-OH had a relatively low hydrodynamic size (~ 20 nm) and close to neutral zeta 
potential (~ -15 mV) (Table S1), which indicated the formation of a dense SAM on the USPIONs’ surface. 
Mixed peptide coated USPIONs formed with the mono-phosphorylated peptidol 2PG-S*VVVT-ol or the 
bis-phosphorylated peptide 2PG-S*VVVT-PEG4-ol were similarly affected by the ligand used and were 
most stable with the ligand (PO3H2)-S-C16-OH (Figures 3E,F). The ethylene glycol moiety on the peptide 
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2PG-S*VVVT-PEG4-ol did not affect the stability of mixed peptide coated USPIONs. Overall, the com-
bination of the peptidol 2PG-S*VVVT-ol and the ligand (PO3H2)-S-C16-OH provided the greatest perfor-
mance for mixed peptide coated USPIONs. 
Cell toxicity and non-specific binding. Two highly stable USPIONs preparations were selected for 
further in vitro evaluation: the single peptide 2PG-S*VVVT-PEG4-ol and the mixed peptide 2PG-
S*VVVT-ol:(PO3H2)-S-C11-EG3-OH (70:30, mole:mole) coated USPIONs. We evaluated the cell tox-
icity of the two preparations in vitro with PLC/PRF5 cells. We measured cell growth using a CellTiter 
96® AQueous One Solution Cell Proliferation Assay (MTS). We observed no toxicity compared to a 
control (untreated cells) after 2 days incubation at 37°C with either 2PG-S*VVVT-PEG4-ol or 2PG-
S*VVVT-ol:(PO3H2)-S-C11-EG3-OH (70:30, mole:mole) coated USPIONs at 100 µg/mL of Fe (Figure 
4A,B). We also tested the non-specific binding of both preparations after overnight incubation at 37°C 
with PLC/PRF5 cells. Cell staining with Prussian blue reagent showed no detectable non-specific binding 
for either peptide coated USPIONs preparation at 10 µg/mL and at 100 µg/mL of Fe (Figure 4F,G). How-
ever, the slight increase of the cell viability observed at the highest concentration, i.e., 100 µg/mL, may 
be due to the potential presence of peptide coated USPIONs non-specifically bound to the cells and con-
tributing to the absorbance of the samples at 490 nm, which is the readout of the cytotoxicity assay (Fig-
ures 4A,B). Alternatively, the low level of cell-associated USPIONs (not detected by the Prussian blue 
assay), may trigger a cellular response that increases mitochondrial membrane potential, and hence MTT 
assay signal. In any event, these USPIONs are not cytotoxic. 
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Figure 4. In vitro evaluation of peptide coated USPIONs. Cell viability assay of selected peptide coated 
USPIONs with PLC/PRF5 cells: (A) 2PG-S*VVVT-PEG4-ol and (B) 2PG-S*VVVT-ol:(PO3H2)-S-C11-
EG3-OH (70:30, mole:mole) coated USPIONs showed no cell toxicity at the test concentration of 100 
µg/mL of Fe after 48 h of incubation at 37°C. Cell non-specific binding test of peptide coated USPIONs 
with PLC/PRF5 cells. (C) Control sample showing PLC/PRF5 cells incubated without USPIONs. Cells 
were incubated overnight at 37°C with (D) TMAOH coated USPIONs, (E-F) 2PG-S*VVVT-PEG4-ol 
and (G-H) 2PG-S*VVVT-ol: (PO3H2)-S-C11-EG3-OH (70:30, mole:mole) coated USPIONs at the test 
concentration of 10 µg/mL (E,G) and 100 µg/mL (D,F,H) of Fe. Cells were stained with Prussian blue 
reagent and counterstained with Nuclear Fast Red solution. All experiments were repeated three times 
and presented as average and standard deviation. 
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Magnetic relaxation performance. The magnetic resonance relaxivities r1 and r2 of 2PG-S*VVVT-
PEG4-ol and 2PG-S*VVVT-ol:(PO3H2)-S-C11-EG3-OH (70:30, mole:mole) coated USPIONs were char-
acterized with a 7T magnetic resonance imaging system (Table 4 and Figures S46-49). We also compared 
their performance to the commercial MRI contrast agents Magnevist® and Resovist®. 2PG-S*VVVT-
PEG4-ol and 2PG-S*VVVT-ol:(PO3H2)-S-C11-EG3-OH (70:30, mole:mole) coated USPIONs presented 
high transverse relaxivity coefficients (r2), i.e., 217.8 and 173.9 mM-1.s-1 respectively. Importantly, r2/r1 ra-
tios define the quality of MRI contrast agents dedicated to either T1 or T2-weighted imaging.30 The r2/r1 
ratio of T1 contrast agent Magnevist® was close to 1. Typically, T2 contrast agents such as Resovist® 
have higher r2/r1 ratios. The peptide coated USPIONs demonstrated greater r2/r1 ratios than the commercial 
T2 contrast agent Resovist® (r2/r1 = 69.4), i.e., 90.8 and 108.7 for 2PG-S*VVVT-PEG4-ol and 2PG-
S*VVVT-ol:(PO3H2)-S-C11-EG3-OH (70:30, mol:mol) coated USPIONS respectively. 
Table 4. Longitudinal and transverse relaxivities of commercial magnetic resonance imaging contrast 
agents and peptide coated USPIONs. 
Peptide coated USPIONs / Commercial contrast agents r1 (mM-1.s-1) r2 (mM-1.s-1) r2/r1 ratios 
Magnevist® 3.8 6.2 1.6 
Resovist® 3.5 242.9 69.4 
2PG-S*VVVT-ol: (PO3H2)-S-C11-EG3-OH (70:30, mol:mol) 1.6 173.9 108.7 
2PG-S*VVVT-PEG4-ol 2.4 217.8 90.8 
 
In vivo liver and tumor magnetic resonance imaging. We next tested the performance of 2PG-
S*VVVT-PEG4-ol coated USPIONs in vivo contrast-enhanced T2-weighted MRI in NCr nude mice using 
a 7T Bruker Clinscan. Intramuscular contrast enhancement was first evaluated using a 10 mg Fe per kg 
of mouse body weight injection of the peptide coated USPIONs in the hind limb. Images confirmed a 
strong 80% decrease of the MRI signal (Figure S50). Iron oxide nanoparticles contrast agents have been 
for long proposed and approved for clinical contrast-enhanced T2-weighted MRI of the liver, because 
they are promptly engulfed by Kupffer cells and macrophages prior to storage and metabolism in the 
liver.31 We injected intravenously a dose of 1.0 mg Fe per kg of 2PG-S*VVVT-PEG4-ol coated USPIONs 
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into NCr nude mice. As anticipated, we observed a strong and persistent decrease of the signal (48 ± 4 % 
at 0.5 h and 52 ± 7 % at 1 h) in the liver during T2-weighted MRI (Figure 5A,B). The application of 
USPIONs as contrast agents has been extended to the imaging of liver lesions, such as those associated 
with cirrhosis and tumors, using T2-weighted MRI to obtain pseudo positive contrast signals, because of 
the differences in vascularity and Kupffer cell activity of affected and healthy liver tissues.31,32 To evaluate 
the use of our peptide coated USPIONs for the imaging of liver tumors, we performed a T2-weighted 
MRI on an orthotopic liver tumor model established by inoculation of PLC/PRF5 cells into the liver of 
nude mice. Once the tumors reached 5 mm, we injected intravenously the 2PG-S*VVVT-PEG4-ol coated 
USPIONs at a dose of 20 mg of Fe per kg and monitored the contrast-to-noise (CNR) ratios of tumor-to-
liver contrast enhancement provided by USPIONs. We found a significant CNR gain at 1 h (28 ± 8 %) 
and enhancement of the definition of the liver tumors contour (Figures 5C,D). Histopathological analysis 
showed the presence of the peptide coated USPIONs in the liver of mice after 1 h post injection (Figures 
5E,F). Interestingly, the presence of the peptide coated USPIONs in healthy liver tissues was clearly con-
firmed (Figure 5E - high right region, and Figure 5F) and we noted the absence of peptide coated USPI-
ONs in the tumor region of the liver (Figure 5E - low left region). The utilization of the peptide coated 
USPIONs may, therefore, contribute to the imaging of early liver cancer lesions by MRI. 
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Figure 5. In vivo MRI with the 2PG-S*VVVT-PEG4-ol coated USPIONs contrast agent. (A) In vivo MR 
images in coronal (upper) and transverse (lower) plane of NCr nude mouse at 0, 0.5 and 1 h after intrave-
nous injection of 2PG-S*VVVT-PEG4-ol coated USPIONs. (B) Quantification of liver contrast collected 
at 0, 0.5 and 1 h after accumulation of peptide coated USPIONs in NCr nude mice at dose of 1.0 mg Fe 
per kg. (C) In vivo MR images in coronal (upper) and transverse (lower) plane of orthotopic xenograph 
liver tumor model at 0, 0.5 and 1 h after intravenous injection of 2PG-S*VVVT-PEG4-ol coated USPI-
ONs. Dashed circle indicates the tumor location. (D) Quantification of contrast-to-noise ratio (CNR) of 
tumor-to-liver contrast at 0, 0.5 and 1 h after accumulation of 2PG-S*VVVT-PEG4-ol coated USPIONs 
at dose of 2.0 mg Fe per kg. (E, F) Histopathological analysis of liver of mice after 1 h post intravenous 
injection of 2PG-S*VVVT-PEG4-ol coated USPIONs at dose of 2.0 mg Fe per kg. Scale bar is 100 µm. 
CONCLUSION 
The development of highly biocompatible and performing USPIONs contrast agents dedicated to in 
vivo MRI applications relies strongly on the quality of their coating. We designed a library of short 
peptides and ligands that are capable of forming highly stable SAMs on the surface of USPIONs. The bis-
phosphorylated peptides and ligands outperformed their homologues with other known anchor groups 
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commonly used to cap iron oxide nanoparticles, e.g., DOPA, carboxylic acid. The peptide coated 
USPIONs were readily prepared with high yields after purification by size-exclusion chromatography 
(94%) and possessed a narrow hydrodynamic size dispersion (18 ± 8 nm) with near neutral charge (-14 ± 
2 mV). With our funnel selection process, we found that 2PG-S*VVVT-PEG4-ol coated USPIONs 
provided long term stability against electrolyte-induced aggregation in physiological conditions, absence 
of detectable non-specific binding to live cells and no cytotoxicity at high concentrations. Interestingly, 
the peptide coated USPIONs demonstrated strong r1 and r2 relaxivities and high r2/r1 ratios that 
outperformed commercially available contrast agents. Finally, 2PG-S*VVVT-PEG4-ol coated USPIONs 
provided strong and lasting contrast enhancement during in vivo liver and tumor liver T2-weighted MRI. 
The development of well-designed peptide coated USPIONs by functionalization with biomarkers will 
enable, for example, the tracking of specific tissues such as breast cancer tumors and provide targeted 
contrast agents for early cancer diagnosis by in vivo high-resolution contrast-enhanced MRI. 
MATERIALS AND METHODS 
Materials and Reagents. Oleic acid coated iron oxide nanoparticles in chloroform were purchased 
from Ocean NanoTech, LLC (San Diego). The alkyl phosphorothioic acid ligands were purchased from 
Prochimia (ProChimia Surfaces Sp. z o.o., Sopot, Poland). Customized ligands and peptides were pur-
chased from Peptide and Protein Research (PPR Ltd, Hampshire, UK). Dimethyl sulfoxide (99%), fer-
rozine [3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt hydrate] (97%), 
hydroxylamine.HCl, ammonium hydroxide, tetramethylammonium hydroxide (96%) (TMAOH), iron 
(III) chloride hexahydrate, Tween 20, HEPES and PBS buffers were purchased from Sigma Aldrich (Sin-
gapore). FBS and DMEM were purchased from Thermofisher, Life Technologies Holdings PTE LTD 
(Singapore). Magnevist® was purchased from Zuellig Pharma (Singapore). Nanosep centrifugal devices 
10 kDa were purchased from PALL Corp. (Portsmouth, Hants, UK). UV-visible spectra were obtained 
using a SpectraMax Plus spectrophotometer (Molecular Devices, Oregon, USA) and 384 wells plates 
from Corning (Lowell, US). Crystal structures of the USPIONs were obtained with a General Area De-
tector Diffraction System (GADDS) XRD instrument from Bruker. All experiments were conducted using 
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milliQ water. µ-Slide angiogenesis were obtained from Ibidi. Prussian blue staining was done with 1:1 
(v:v) mixture of 5% (w:v) potassium ferrocyanide K4Fe(CN)6. 3H20 (Sigma) and 2% (v:v) HCl (Merck). 
Optical imaging was done using a Nikon TS100 microscope system. Cell viability was measured with a 
Promega CellTiter 96® AQueous One Solution Cell Proliferation kit. Absorbance at 490 nm was read 
using the Perkin Elmer EnSpire® Multimode Plate Reader system. 
Preparation of tetramethylammonium hydroxide coated USPIONs. In a 15 mL tube, 996 µL of 
oleic acid coated USPIONs (10 nm in diameter, 25 mg/mL of Fe) in chloroform were mixed for 30 min 
at room temperature with 3 mL of 2 mM of TMAOH in water. Chloroform (2 mL) was added and the two 
phases were separated overnight at 5°C. The aqueous phase containing the TMAOH coated USPIONs 
was then collected and placed into a 15 mL tube and washed 3 times with 18 mL acetone for 5 min. The 
TMAOH coated USPIONs were collected by centrifugation (x1000 rpm for 5 min) and dried under a 
fume hood to remove the remaining solvent. The TMAOH coated USPIONs were then suspended in 4 
mL of 0.1 % (w/v) TMAOH in water and stored at 5°C. A Fe content of 93 mM in the TMAOH coated 
USPIONs stock solution was determined by ferrozine assay. 
Preparation of peptide coated USPIONs. To prepare peptide coated USPIONs, 1 volume of 2 mM 
solution of peptide/ligand (either unitary or mixed) prepared in 25:75 (v/v) DMSO:water was mixed with 
0.05 volume of 1% (v/v) Tween 20 in water. Then, 0.1 volume of TMAOH coated USPIONs (93 mM Fe 
content) in 0.1% (w/v) of TMAOH in water and 8.9 volumes of water were added and mixed at room 
temperature for an hour. A volume of HEPES 10X buffer (200 mM HEPES, 1 M NaCl, pH 7.4) was 
added and the solution was mixed at room temperature overnight. 
Size-exclusion chromatography. Sephadex G25 superfine (10 mL) was prepared, loaded into a column 
and stored in 25:75 (v/v) ethanol:water solution. The column was equilibrated with 0.0005% (v/v) Tween 
20 in water. A mL peptide coated USPIONs was concentrated to approximately 100 µL by centrifugation 
on a 10 kDa cut-off Nanosep filter. Then, the USPIONs were loaded on the column and eluted under 
gravity using water with 0.0005% (v/v) Tween 20 as the mobile phase. Approximately 1.4 mL colored 
fractions were collected in the excluded volume. 
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Calculation of the yield of peptide coated USPIONs. The yield of preparations of peptide coated 
USPIONs is calculated based on the absorbance at 300 nm of the samples before and after coating and 
purification by size-exclusion chromatography with G25 resin columns. 
Yield in % = 100*(A300 after G25/A300 control) 
A300 after G25 is the absorbance at 300 nm of the sample after purification with G25 resin and the total volume 
of the sample adjusted to 1 mL with water. A300 control is the absorbance at 300 nm of the same sample before 
ligand exchange with peptides and the total volume of the sample adjusted to 1 mL with water. 
All experiments were repeated at least two times and presented as average and standard deviation. 
Normalized aggregation parameter. To allow the comparison of results from different electrolyte-
induced aggregation experiments, we defined an aggregation parameter (AP) as follows: 
AP=(A450nm-Aref450nm)/(A310nm-Aref310nm) 
A450nm and A310nm are absorbance values of solutions of nanoparticles at 450 nm and 310 nm, respectively. 
The empiric wavelength of 450 nm has been chosen to reflect the aggregated state of the nanoparticles. 
Aref450nm and Aref310nm are absorbance values of water at 450 nm and 310 nm. To allow direct comparison of 
results obtained with different peptide coated USPIONs, this primary aggregation parameter was then 
normalized by dividing the aggregation parameter values of each experiment by the initial aggregation 
parameter value of the sample before the stability test. This provided a Normalized Aggregation Parameter 
(NAP). A stable sample should have a stable UV-visible absorbance spectrum and hence, its NAP is near 
1. An increase of the NAP indicated instability and eventually aggregation of the USPIONs. 
All experiments were repeated at least two times and presented as average and standard deviation. 
Ferrozine assay. A stock solution of 10 mM ferrozine solution was prepared by dissolving 51.4 mg 
ferrozine (492.46 g/mol) and 1 g  hydroxylamine.HCl (69.49 g/mol) in a mixture of 5 mL of HCl (37%, 
v:v) and 5 mL of water. Ammonium buffer (8 mL, pH 5.5) was prepared by dissolving 20 g ammonium 
acetate (77.08 g/mol) in 17.50 mL ammonium hydroxide in 50 mL of water before addition of 30 mL HCl 
(37%, v:v). An iron standard solution at 1 mol/L of Fe was prepared by dissolving 0.067 g FeCl3.6H2O 
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(270.30 g/mol) in 250 µL of water. Subsequent dilutions of this standard solution were made to prepare a 
calibration curve. 
The iron content in each standard solution and USPIONs preparation was determined by mixing 1 µL 
of the sample with 100 µL of a 10 mM ferrozine solution and 50 µL water. The samples were heated to 
60°C for 30 min. The ammonium buffer solution (350 µL) was added to the sample which was then 
analyzed by UV-visible spectrometry to prepare a calibration curve and quantify the iron content of each 
USPIONs sample. 
Dynamic light scattering and zeta potential characterization. Dynamic light scattering (DLS) was 
performed using a Malvern ZetasizerNano ZS instrument equipped with a 633 nm HeNe laser to measure 
the hydrodynamic particle size and distribution in solution. The characterization of the zeta potential of 
peptide coated USPIONs was performed with the same instrument through application of a voltage stim-
ulus ranging from -100 to 100 mV between the electrodes of the dual purpose cuvette. A statistical average 
of three readings per sample was taken for each measurement. 
High-resolution transmission electron microscopy. The USPIONs samples were diluted into ethanol 
(for the oleic acid coated USPIONs in chloroform) or water (for the TMAOH and peptide coated USPI-
ONs) and deposited on Ultrathin Carbon (<3 nm) on Carbon Holey support film TEM grids (Ultrathin 
Carbon / Holey Support on 400 mesh, Pelco International, USA). The USPIONs were analysed with a 
Philips CM300 high resolution analytical TEM/STEM. The core size of the USPIONs was determined 
with ImageJ v1.47e software using the macro ‘ParticleSizeAnalyzer’. A minimum of 100 USPIONs were 
counted to determine the size distribution of the sample. 
Cell viability assay. PLC/PRF5 cells were dissociated using trypsin and counted. The cells were then 
washed and suspended at a density of 400,000 cells per mL in Dulbecco’s minimal Eagle’s medium 
(DMEM) with 5 % (v/v) fetal bovine serum (FBS) (v:v). Aliquots (50 µL, 20,000 cells) were placed in 
each well of 96 well flat bottom plates. The cells were allowed to adhere overnight at 37°C. 
The USPIONs dispersed in 0.0005% (v/v) Tween 20 in water were diluted in Dulbecco’s minimal 
Eagle’s medium (DMEM) with 10 % (v/v) fetal bovine serum (FBS) to prepare a series of samples 
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containing between 400 ng/mL and 200 µg/mL of Fe. Each USPIONs solution (50 µL) was added to the 
cells in the 96 well plates and incubated for 48 hours at 37°C. 
Cell growth was used as a proxy for cytotoxicity and was measured using a CellTiter 96® AQueous 
One Solution Cell Proliferation Assay (MTS). The growth of treated cells growth was reported as a 
percentage of the control untreated cells. All experiments were repeated at least three times and presented 
as average and standard deviation. 
Cell non-specific binding. PLC/PRF5 cells were dissociated using trypsin and counted. The cells were 
then washed and suspended at a density of 106 cells per mL. Aliquots (50 µL, 20,000 cells) were seeded 
in each well in a µ-Slide plate from Ibidi. The cells were allowed to adhere overnight at 37°C. 
Peptide coated USPIONs in 0.0005% (v/v) Tween 20 in water were diluted in Dulbecco’s minimal 
Eagle’s medium (DMEM) with 10 % (v/v) fetal bovine serum (FBS) (v:v)  to prepare samples containing 
10 µg/mL to 100 µg/mL of Fe. The medium from each well was removed and replaced with 50 µL of 
USPIONs solution and incubated overnight at 37°C. 
The medium containing the USPIONs was washed away from the wells thoroughly with PBS. The cells 
were then fixed with a 4% (v/v) paraformaldehyde solution in PBS for 15 min at room temperature. The 
excess paraformaldehyde was removed by washing with water. Prussian blue staining reagent (50 µL) 
containing 2.5% (w/v) potassium ferrocyanide trihydrate (K4Fe(CN)6. 3H20) in water and 1% (v/v) HCl 
were added to each well and incubated at room temperature for 30 min. The staining reagent was then 
thoroughly washed away with water. The cells were counterstained for 30 min at room temperature with 
50 µL of Nuclear Fast Red solution in water. The excess of solution was then removed by washing away 
with water. The non-specific association of the USPIONs to the cells was finally visualized by light 
microscope. 
Magnetic resonance imaging phantom. Peptide coated USPIONs and the commercial MRI contrast 
agents Magnevist® and Resovist® were serially diluted in 500 µL of water to give 5 concentrations of 
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iron or gadolinium in the case of Magnevist®. The phantoms were then prepared in 1 mL syringes by 
filling them to 0.4 mL mark and sealing the ends with parafilm. 
The magnetic resonance relaxivities r1 and r2 of peptide coated USPIONs and the commercial MRI 
contrast agents Magnevist® and Resovist® were determined using a 7 Tesla Bruker ClinScan magnetic 
resonance imaging system. T1 relaxation times were determined by an inversion recovery experiment 
with a number of inversion times (TI) (9 TIs; TI: 41–4000 ms; repetition time (TR): 5000 ms; echo time 
(TE): 7.7 ms). T2 relaxation times were determined from a multiecho spin-echo sequence (TR: 4000 ms; 
TE: 17.9-250.6 ms). The longitudinal (r1) and transverse (r2) relaxivities were obtained from the slope of 
1/T1 or 1/T2 versus molar concentration plots. 
Contrast enhancement in muscle. All animal experiments were approved by the Institutional Animal 
Care and Use Committee (IACUC #151089). In vivo MRI was performed using NCr nude mouse as a 
model. Peptide coated USPIONs were diluted in saline to a concentration of 0.2 mg Fe per mL. The 
USPIONs were injected intramuscularly into the left hind limb of the animal at a dose of 1 mg Fe per kg 
of mouse body weight. The transverse and coronal plane images were scanned using a 7T Bruker Clinscan 
with the following parameters: T2-weighted turbo spin echo sequence TSE, TR/TE=1010/56 ms, 320x320 
matrices, slice thickness = 0.8 mm, averages = 2. 
Liver magnetic resonance imaging. In vivo MRI of liver were performed using NCr nude mouse as a 
model. Peptide coated USPIONs were diluted in saline to a concentration of 0.2 mg Fe per mL. The 
USPIONs were injected intravenously in the tail vein at a dose of 1 mg Fe per kg of mouse body weight. 
The transverse and coronal plane images were scanned at pre-injection, 30 mins and 60 mins post-injec-
tion using a 7T Bruker Clinscan (n=3) with the following parameters: T2 weighted turbo spin echo se-
quence TSE, TR/TE=1010/56 ms, 320 x 320 matrices, slice thickness = 1 mm, averages = 2 (transverse), 
4 (coronal). 
The SNR (signal-to-noise ratio) was calculated using the equation: 
SNRliver=SIliver/SDnoise 
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where SI represents signal intensity and SD represents s.d. The SNR changes of the ROI was calculated 
by the equation:  
ΔSNR=(SNRpost–SNRpre)/SNRpre. 
The experiment was repeated three times and presented as average and standard deviation. 
Detection of liver tumor by magnetic resonance imaging. The orthotopic liver tumor model was 
established by inoculation of PLC/PRF5 cells into the liver of nude mice. When the tumors reached 5 mm 
in diameter, in vivo MRI of liver was performed. The USPIONs were injected intravenously in the tail 
vein at a dose of 2 mg Fe per kg of mouse body weight. The axial, coronal and sagittal planes were scanned 
at 0, 30 and 60 min post injection using a 9.4T Bruker Biospec (n=3). T2-weighted, turboRARE sequence, 
TR/TE= 570/23ms, 320 x 320 matrices, slice thickness = 1 mm, averages = 2, Rare factor = 8. 
The SNR was calculated using the equation: 
SNRliver=SIliver/SDnoise 
where SI represents signal intensity and SD represents s.d. 
CNR (contrast-to-noise ratio) was calculated using the formula: 
CNR = (SNRtumour – SNRliver)/ SNRtumour. 
The experiment was repeated three times and presented as average and standard deviation. 
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